Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 33 results for "novartis india"

Novartis: Eyes on Roche stake sale

According to global media, Novartis is discussing options with banks for selling its near $14-billion stake in rival Roche, potentially providing cash for new deals. Novartis built up its one-third stake in Roche's voting stock between 2001 and 2003 ...
 Hindu Business Line5 days ago

Rupee gains for second straight day

The Indian rupee gained for the second straight day on Wednesday on sustained selling of dollars by banks and exporters. In Picture: Tourists walk past a currency exchange shop at a shopping arcade in New Delhi August 20, 2013. Reuters file The ...
 International Business Times India1 week ago

Weekly: Marginal gains for Sensex, Nifty

17:45 IST For the week, BSE Sensex closed at 25,838 (up 0.8%) and NSE Nifty at 7,899 (up 0.6%) Article saved successfully to my page. In last two months, prosperity seems to be visiting the street even as indices appear to be racing ...
 India Infoline1 week ago

Novartis launches Scapho for the treatment of moderate-to-severe psoriasis in India

Novartis Healthcare Private Limited (NHPL) announced the launch of Scapho(secukinumab)150 mg, for the treatment ofmoderate-to-severe plaque psoriasis in adult patients. Scaphois an injectable medicine and the first interleukin-17A (IL-17A) ...
 EHealth Magazine1 month ago Drug firm Novartis launches Scapho for treatment of psoriasis  Moneycontrol.com1 month ago Novartis Healthcare gets DCGI nod to market Scapho for first-line treatment of moderate-to-severe psoriasis  PharmaBiz1 month ago

Novartis Healthcare launches psoriasis treatment drug in India

NEW DELHI: Novartis Healthcare has launched secukinumab, used for the treatment of plaque psoriasis in adult patients, in India. The company has launched the drug in the strength of 150 mg, for the treatment of moderate-to-severe plaque psoriasis ...
 Economic Times1 month ago
India Infoline

Novartis India posts Rs 60 cr net profit

Novartis India today reported a net profit of Rs 59.81 crore for the third quarter ended December 31, 2015. The company had posted a net loss of Rs 1.18 crore in the same period last fiscal, Novartis India said in a BSE filing. Net sales during the period ...
 Business Line2 months ago Novartis India Q3 net profit at Rs. 59.8 Cr  India Infoline2 months ago Novartis India Q3 net at Rs 60 crore  Economic Times2 months ago Novartis India Q3 net at Rs 60 cr  Money Control2 months ago

Novartis Healthcare launches Scapho (Secukinumab) for treatment of psoriasis

S ecukinumab is the first recombinant fully human monoclonal antibody selective for interleukin-17A, it has been approved by the DCGI for the treatment of moderate-to-severe plaque psoriasis Novartis Healthcare announced the launch of Scapho ...
 Financial Express1 month ago

Budget very strategic, it is work in progress: Novartis

Budget is very strategic, it is obviously work in progress, and the nine pillars which the finance minister mentioned are great, says Ranjit Shahani, vice-chairman and managing director Novartis India
 Money Control1 month ago

No Respite for Indian Indices

Posted by Equitymaster Following a negative trend since the opening of trade, the Indian indices have continued to remain under pressure in the post noon trading session. Sectoral indices are trading on a negative note with stocks from the power , realty and ...
 Equitymaster.com2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less